Alessio Di Fonzo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/707179/publications.pdf

Version: 2024-02-01

116 papers 8,140 citations

94433 37 h-index 51608 86 g-index

121 all docs

121 docs citations

times ranked

121

10049 citing authors

#	Article	IF	Citations
1	A Practical Approach to Early-Onset Parkinsonism. Journal of Parkinson's Disease, 2022, 12, 1-26.	2.8	19
2	VPS13C-associated Parkinson's disease: Two novel cases and review of the literature. Parkinsonism and Related Disorders, 2022, 94, 37-39.	2.2	8
3	Dysautonomia in Parkinson's Disease: Impact of Glucocerebrosidase Gene Mutations on Cardiovascular Autonomic Control. Frontiers in Neuroscience, 2022, 16, 842498.	2.8	6
4	Transcriptomic characterization of tissues from patients and subsequent pathway analyses reveal biological pathways that are implicated in spastic ataxia. Cell and Bioscience, 2022, 12, 29.	4.8	1
5	Role of Lysosomal Gene Variants in Modulating <scp><i>GBA</i></scp> â€Associated Parkinson's Disease Risk. Movement Disorders, 2022, 37, 1202-1210.	3.9	17
6	Progressive myoclonus without epilepsy due to a NUS1 frameshift insertion: Dyssynergia cerebellaris myoclonica revisited. Parkinsonism and Related Disorders, 2022, 98, 53-55.	2.2	4
7	Clinical uses of Bupropion in patients with Parkinson's disease and comorbid depressive or neuropsychiatric symptoms: a scoping review. BMC Neurology, 2022, 22, 169.	1.8	4
8	The Italian tremor Network (TITAN): rationale, design and preliminary findings. Neurological Sciences, 2022, 43, 5369-5376.	1.9	12
9	<scp><i>TWNK</i></scp> in Parkinson's Disease: A Movement Disorder and Mitochondrial Disease Center Perspective Study. Movement Disorders, 2022, 37, 1938-1943.	3.9	10
10	Spinal direct current stimulation (tsDCS) in hereditary spastic paraplegias (HSP): A sham-controlled crossover study. Journal of Spinal Cord Medicine, 2021, 44, 46-53.	1.4	29
11	Leukoencephalopathy with calcifications and cysts: Genetic and phenotypic spectrum. American Journal of Medical Genetics, Part A, 2021, 185, 15-25.	1.2	15
12	Expanding the genotypic and phenotypic spectrum of Betaâ€propeller poteinâ€associated neurodegeneration. European Journal of Neurology, 2021, 28, e25-e27.	3. 3	0
13	Unravelling Genetic Factors Underlying Corticobasal Syndrome: A Systematic Review. Cells, 2021, 10, 171.	4.1	8
14	A Novel Homozygous <scp><i>VPS11</i></scp> Variant May Cause Generalized Dystonia. Annals of Neurology, 2021, 89, 834-839.	5.3	13
15	Clinical features and disease course of patients with acute ischaemic stroke just before the Italian index case: Was COVID-19 already there?. Internal and Emergency Medicine, 2021, 16, 1247-1252.	2.0	O
16	Targeting the Autonomic Nervous System for Risk Stratification, Outcome Prediction and Neuromodulation in Ischemic Stroke. International Journal of Molecular Sciences, 2021, 22, 2357.	4.1	19
17	Genetic variants in levodopa-induced dyskinesia (LID): A systematic review and meta-analysis. Parkinsonism and Related Disorders, 2021, 84, 52-60.	2.2	13
18	HOPS-associated neurological disorders (HOPSANDs): linking endolysosomal dysfunction to the pathogenesis of dystonia. Brain, 2021, 144, 2610-2615.	7.6	20

#	Article	IF	CITATIONS
19	Motor and cognitive outcomes of cerebello-spinal stimulation in neurodegenerative ataxia. Brain, 2021, 144, 2310-2321.	7.6	38
20	Screening of LRP10 mutations in Parkinson's disease patients from Italy. Parkinsonism and Related Disorders, 2021, 89, 17-21.	2.2	5
21	Sodium Levels Predict Disability at Discharge in Guillain-Barré Syndrome: A Retrospective Cohort Study. Frontiers in Neurology, 2021, 12, 729252.	2.4	2
22	A 79-year-old man with unexplained recurrent syncope and severe orthostatic hypotension. Internal and Emergency Medicine, 2021, , 1.	2.0	0
23	Parkinsonism and ataxia. Journal of the Neurological Sciences, 2021, , 120020.	0.6	2
24	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq0 0 0 rgBT /Overlock 1	0 Jf 50 54	1,430 (editio
25	Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories. Molecular Neurodegeneration, 2021, 16, 82.	10.8	28
26	Parkinson's disease in Gaucher disease patients: what's changing in the counseling and management of patients and their relatives?. Orphanet Journal of Rare Diseases, 2020, 15, 262.	2.7	3
27	A rapid and low-cost test for screening the most common Parkinson's disease-related GBA variants. Parkinsonism and Related Disorders, 2020, 80, 138-141.	2.2	7
28	Dystoniaâ€ataxia syndrome with permanent torsional nystagmus caused by ECHS1 deficiency. Annals of Clinical and Translational Neurology, 2020, 7, 839-845.	3.7	10
29	<scp><i>GBA</i>â€Related</scp> Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort. Movement Disorders, 2020, 35, 2106-2111.	3.9	83
30	Comprehensive Genomic Analysis Reveals the Prognostic Role of LRRK2 Copy-Number Variations in Human Malignancies. Genes, 2020, 11, 846.	2.4	3
31	Late-onset leukoencephalopathy in a patient with recessive EARS2 mutations. Neurology: Genetics, 2020, 6, e488.	1.9	0
32	Pharmacological antagonism of kainate receptor rescues dysfunction and loss of dopamine neurons in a mouse model of human parkin-induced toxicity. Cell Death and Disease, 2020, 11, 963.	6.3	13
33	A case report of late-onset cerebellar ataxia associated with a rare p.R342W TGM6 (SCA35) mutation. BMC Neurology, 2020, 20, 408.	1.8	3
34	Systemic involvement in adultâ€onset leukoencephalopathy with intracranial calcifications and cysts (Labrune syndrome) with a novel mutation of the SNORD118 gene. European Journal of Neurology, 2020, 27, 2329-2332.	3.3	6
35	Childhoodâ€onset dystonia with cerebellar signs: expanding the spectrum of GNAL mutations. European Journal of Neurology, 2020, 27, e66-e67.	3.3	1
36	Design and Operation of the Lombardy Parkinson's Disease Network. Frontiers in Neurology, 2020, 11, 573.	2.4	3

#	Article	IF	CITATIONS
37	Nucleo–cytoplasmic transport defects and protein aggregates in neurodegeneration. Translational Neurodegeneration, 2020, 9, 25.	8.0	33
38	Microscopic Polyangiitis With Selective Involvement of Central and Peripheral Nervous System: A Case Report. Frontiers in Neurology, 2020, 11, 269.	2.4	3
39	SLC25A46 mutations in patients with Parkinson's Disease and optic atrophy. Parkinsonism and Related Disorders, 2020, 74, 1-5.	2.2	16
40	The Role of Mitochondria in Neurodegenerative Diseases: the Lesson from Alzheimer's Disease and Parkinson's Disease. Molecular Neurobiology, 2020, 57, 2959-2980.	4.0	180
41	The SPID-GBA study. Neurology: Genetics, 2020, 6, e523.	1.9	37
42	Syncope and autonomic failure in a middle-aged man. Internal and Emergency Medicine, 2019, 14, 271-274.	2.0	0
43	Understanding the pathogenesis of multiple system atrophy: state of the art and future perspectives. Acta Neuropathologica Communications, 2019, 7, 113.	5.2	56
44	Validation of the Italian version of the PSP Quality of Life questionnaire. Neurological Sciences, 2019, 40, 2587-2594.	1.9	5
45	Loss of the nucleoporin Aladin in central nervous system and fibroblasts of Allgrove Syndrome. Human Molecular Genetics, 2019, 28, 3921-3927.	2.9	9
46	Validation of the Italian version of carers' quality-of-life questionnaire for parkinsonism (PQoL) Tj ETQq0 0 0	rgBT/Ove	rlock 10 Tf 50
47	GBA, Gaucher Disease, and Parkinson's Disease: From Genetic to Clinic to New Therapeutic Approaches. Cells, 2019, 8, 364.	4.1	187
48	Neurofascin (NFASC) gene mutation causes autosomal recessive ataxia with demyelinating neuropathy. Parkinsonism and Related Disorders, 2019, 63, 66-72.	2.2	25
49	Parkinsonism in diseases predominantly presenting with dystonia. International Review of Neurobiology, 2019, 149, 307-326.	2.0	4
50	In vitro models of multiple system atrophy from primary cells to induced pluripotent stem cells. Journal of Cellular and Molecular Medicine, 2018, 22, 2536-2546.	3.6	11
51	Real life evaluation of safinamide effectiveness in Parkinson's disease. Neurological Sciences, 2018, 39, 733-739.	1.9	22
52	A de novo C19orf12 heterozygous mutation in a patient with MPAN. Parkinsonism and Related Disorders, 2018, 48, 109-111.	2.2	15
53	Clinical Reasoning: A 75-year-old man with parkinsonism, mood depression, and weight loss. Neurology, 2018, 90, 572-575.	1.1	2
54	Mitochondrial dysfunction in fibroblasts of Multiple System Atrophy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3588-3597.	3.8	32

#	Article	IF	CITATIONS
55	Mitochondrial Dysregulation and Impaired Autophagy in iPSC-Derived Dopaminergic Neurons of Multiple System Atrophy. Stem Cell Reports, 2018, 11, 1185-1198.	4.8	46
56	Hallucinations in Neurological Disorders. , 2018, , 99-130.		0
57	Genetics of Movement Disorders and the Practicing Clinician; Who and What to Test for?. Current Neurology and Neuroscience Reports, 2018, 18, 37.	4.2	27
58	The Length of SNCA Rep1 Microsatellite May Influence Cognitive Evolution in Parkinson's Disease. Frontiers in Neurology, 2018, 9, 213.	2.4	21
59	LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study. Lancet Neurology, The, 2018, 17, 597-608.	10.2	101
60	Globus pallidus internus deep brain stimulation in PINK-1 related Parkinson's disease: A case report. Parkinsonism and Related Disorders, 2017, 38, 93-94.	2.2	9
61	<scp>A</scp> daptive deep brain stimulation controls levodopaâ€induced side effects in <scp>P</scp> arkinsonian patients. Movement Disorders, 2017, 32, 628-629.	3.9	96
62	Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease. Advances in Neurobiology, 2017, 14, 3-30.	1.8	66
63	Mutations in TMEM230 are rare in autosomal dominant Parkinson's disease. Parkinsonism and Related Disorders, 2017, 39, 87-88.	2.2	11
64	The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p. Scientific Reports, 2017, 7, 12702.	3.3	62
65	X-linked Parkinsonism with Intellectual Disability caused by novel mutations and somatic mosaicism in RAB39B gene. Parkinsonism and Related Disorders, 2017, 44, 142-146.	2.2	43
66	Progressive Encephalomyelitis with Rigidity and Myoclonus Associated With Anti-GlyR Antibodies and Hodgkin's Lymphoma: A Case Report. Frontiers in Neurology, 2017, 8, 401.	2.4	17
67	Abnormal brain temperature in early-onset Parkinson's disease. Movement Disorders, 2016, 31, 425-426.	3.9	14
68	Generation and characterization of iPSC-derived cortical pyramidal neurons from patients affected by multiple system atrophy. Parkinsonism and Related Disorders, 2016, 22, e119-e120.	2.2	0
69	Mutational analysis of COQ2 in patients with MSA in Italy. Neurobiology of Aging, 2016, 45, 213.e1-213.e2.	3.1	25
70	Autophagy in motor neuron disease: Key pathogenetic mechanisms and therapeutic targets. Molecular and Cellular Neurosciences, 2016, 72, 84-90.	2.2	43
71	Cerebellar and Motor Cortical Transcranial Stimulation Decrease Levodopa-Induced Dyskinesias in Parkinson's Disease. Cerebellum, 2016, 15, 43-47.	2.5	99
72	LRRK2 and GBA mutation analysis in a cohort of Italian familial and sporadic PD. Parkinsonism and Related Disorders, 2016, 22, e167.	2.2	0

#	Article	IF	CITATIONS
73	Adaptive deep brain stimulation in a freely moving parkinsonian patient. Movement Disorders, 2015, 30, 1003-1005.	3.9	198
74	A novel homozygous PLA2G6 mutation causes dystonia-parkinsonism. Parkinsonism and Related Disorders, 2015, 21, 337-339.	2.2	22
75	Juvenile dystonia-parkinsonism syndrome caused by a novel p.S941Tfs1X ATP13A2 (PARK9) mutation. Parkinsonism and Related Disorders, 2015, 21, 1378-1380.	2.2	10
76	Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis. FASEB Journal, 2015, 29, 4614-4628.	0.5	60
77	Cerebellar tDCS: How to Do It. Cerebellum, 2015, 14, 27-30.	2.5	114
78	Obesity and Headache/Migraine: The Importance of Weight Reduction through Lifestyle Modifications. BioMed Research International, 2014, 2014, 1-7.	1.9	24
79	Congenital Myasthenic Syndrome Due to Choline Acetyltransferase Mutations in Infants. Journal of Child Neurology, 2014, 29, 389-393.	1.4	13
80	Lower motor neuron disease with respiratory failure caused by a novel <i>MAPT</i> mutation. Neurology, 2014, 82, 1990-1998.	1.1	21
81	Mutation in the <i>SYNJ1 </i> Gene Associated with Autosomal Recessive, Early-Onset Parkinsonism. Human Mutation, 2013, 34, 1208-1215.	2.5	276
82	Mutations in DNA2 Link Progressive Myopathy to Mitochondrial DNA Instability. American Journal of Human Genetics, 2013, 92, 293-300.	6.2	115
83	The novel mitochondrial tRNAAsn gene mutation m.5709T>C produces ophthalmoparesis and respiratory impairment. European Journal of Human Genetics, 2012, 20, 357-360.	2.8	4
84	Two novel mutations in PEO1 (Twinkle) gene associated with chronic external ophthalmoplegia. Journal of the Neurological Sciences, 2011, 308, 173-176.	0.6	7
85	Unusual adult-onset Leigh syndrome presentation due to the mitochondrial m.9176T>C mutation. Biochemical and Biophysical Research Communications, 2011, 412, 245-248.	2.1	19
86	Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability. Neurogenetics, 2011, 12, 33-39.	1.4	84
87	Autosomal dominant restless legs syndrome maps to chromosome 20p13 (RLSâ€5) in a Dutch kindred. Movement Disorders, 2010, 25, 1715-1722.	3.9	12
88	<i>FBXO7</i> mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology, 2009, 72, 240-245.	1.1	314
89	Pseudoâ€orthostatic and resting leg tremor in a large spanish family with homozygous truncating <i>parkin</i> mutation. Movement Disorders, 2009, 24, 144-147.	3.9	10
90	The Mitochondrial Disulfide Relay System Protein GFER Is Mutated in Autosomal-Recessive Myopathy with Cataract and Combined Respiratory-Chain Deficiency. American Journal of Human Genetics, 2009, 84, 594-604.	6.2	121

#	Article	IF	Citations
91	GIGYF2 mutations are not a frequent cause of familial Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, 703-705.	2.2	22
92	The LRRK2 Arg1628Pro variant is a risk factor for Parkinson's disease in the Chinese population. Neurogenetics, 2008, 9, 271-276.	1.4	61
93	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurology, The, 2008, 7, 583-590.	10.2	1,340
94	<i>LRRK2</i> MUTATION ANALYSIS IN PARKINSON DISEASE FAMILIES WITH EVIDENCE OF LINKAGE TO PARK8. Neurology, 2008, 70, 2348-2349.	1.1	10
95	ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology, 2007, 68, 1557-1562.	1.1	312
96	LRRK2 mutations and Parkinson's disease in Sardiniaâ€"A Mediterranean genetic isolate. Parkinsonism and Related Disorders, 2007, 13, 17-21.	2.2	21
97	Parkin polymorphisms and environmental exposure: Decrease in age at onset of Parkinson's disease. NeuroToxicology, 2007, 28, 698-701.	3.0	15
98	1.283 Clinical and genetic study of a large Dutch family with autosomal dominant restless legs syndrome. Parkinsonism and Related Disorders, 2007, 13, S72.	2.2	0
99	2.119 Parkin polymorphisms and environmental exposure: Reduction of Parkinson's disease age of onset. Parkinsonism and Related Disorders, 2007, 13, S97.	2.2	0
100	Neuropathology of Parkinson's disease associated with the LRRK2 Ile 1371Val mutation. Movement Disorders, 2007, 22, 275-278.	3.9	46
101	High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal. Movement Disorders, 2007, 22, 1194-1201.	3.9	76
102	The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. Human Genetics, 2007, 120, 857-863.	3.8	157
103	SPG11: a consistent clinical phenotype in a family with homozygous Spatacsin truncating mutation. Neurogenetics, 2007, 8, 301-305.	1.4	38
104	LRRK2 G2019S mutation and Parkinson's disease: A clinical, neuropsychological and neuropsychiatric study in a large Italian sample. Parkinsonism and Related Disorders, 2006, 12, 410-419.	2.2	106
105	Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. European Journal of Human Genetics, 2006, 14, 322-331.	2.8	152
106	A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics, 2006, 7, 133-138.	1.4	255
107	Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation. Movement Disorders, 2006, 21, 1144-1147.	3.9	41
108	The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. Journal of Medical Genetics, 2005, 42, e65-e65.	3.2	178

#	Article	IF	CITATIONS
109	A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet, The, 2005, 365, 412-415.	13.7	449
110	The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease. Parkinsonism and Related Disorders, 2005, 11, 521-522.	2.2	70
111	A case of CPT deficiency, homoplasmic mtDNA mutation and ragged red fibers at muscle biopsy. Journal of the Neurological Sciences, 2005, 239, 21-24.	0.6	15
112	POLG mutations in sporadic mitochondrial disorders with multiple mtDNA deletions. Human Mutation, 2003, 22, 498-499.	2.5	100
113	Novel missense mutation and large deletion of GNE gene in autosomal-recessive inclusion-body myopathy. Muscle and Nerve, 2003, 28, 113-117.	2.2	32
114	Remarkable infidelity of polymerase \hat{l}^3A associated with mutations in <i>POLG1</i> exonuclease domain. Neurology, 2003, 61, 903-908.	1.1	60
115	The SPID- & lt;i>GBA Study: The Largest Monocentric Study on Sex Distribution, Penetrance, Incidence, and Association with Dementia of & lt;i>GBA Mutations in Parkinson's Disease. SSRN Electronic Journal, 0, , .	0.4	0
116	Genetic evaluation in phenotypically discordant monozygotic twins with Coats Disease. European Journal of Ophthalmology, 0, , 112067212211077.	1.3	0